双歧杆菌三联活菌制剂防治儿童呼吸道感染继发腹泻临床疗效的meta分析

采用meta分析评价双歧杆菌三联活菌散/胶囊治疗儿童呼吸道感染继发腹泻的临床疗效。

计算机检索中国知网、维普、万方、PubMed、Web of Science和Embase数据库，收集全球范围内在治疗儿童呼吸道感染继发腹泻中使用双歧杆菌三联活菌制剂（散/胶囊）的随机对照研究和前瞻性非随机对照研究，检索时间截至2022年7月，采用Jadad评分量表对纳入文献进行质量评价，采用Cochrane协作网提供的RevMan 5.4分析软件进行数据处理和meta分析。

纳入19篇公开发表的文献进行meta分析，共3 086例患者，治疗组（对照组常规治疗措施+双歧杆菌三联活菌散/胶囊）1 578例，对照组1 508例，meta分析结果显示，治疗组的总体有效率显著高于对照组[OR = 6.54，95% CI（4.03，10.62），P＜0.000 01]，同时，治疗组的显效率优于对照组[OR=4.21，95% CI（2.97，5.97），P＜0.000 01]，并且，相比于对照组，治疗组的腹泻发病率降低[OR = 0.20，95% CI（0.12，0.34），P＜0.000 01]），差异均有统计学意义。

双歧杆菌三联活菌散/胶囊与常规治疗方法相比，可以提高儿童呼吸道感染继发腹泻的治疗总体有效率、治疗显效率，同时有效降低患儿的腹泻发病率。

Viable Bifidobacterium-Lactobacillus-Enterococcus capsules/powder for the treatment of diarrhea secondary to recurrent respiratory infections in children: a meta analysis

ObjectiveTo evaluate the clinical effect of viable Bifidobacterium-Lactobacillus-Enterococcus (BLE) capsules/powder in treating diarrhea secondary to recurrent respiratory infections in children. MethodsDatabases including CNKI, WanFang, VIP, PubMed, Embase and Web of Science were searched to collect randomized controlled trials or prospective non-randomized controlled trials about viable BLE capsules/powder treatment for diarrhea secondary to respiratory infection in children before July 2022. Each article underwent quality assessment according to Jadad scale. RevMan 5.4 provided by Cochrane Collaboration was used for data processing and meta analysis. ResultsA meta-analysis of 19 published literatures was included, involving 3,086 patients, of which 1,578 patients were from the treatment group (conventional therapy plus viable BLE capsules/powder treatment) and 1,508 patients from the control group (conventional therapy alone). Meta-analysis showed that the overall efficiency rate in the treatment group was significantly higher than that in the control group [OR = 6.54, 95% CI (4.03, 10.62), P＜0.000 01]; the significant efficiency rate in the treatment group was better than that in the control group [OR = 4.21, 95% CI (2.97, 5.97), P＜0.000 01]. In addition, the treatment group showed significantly lower diarrhea incidence compared to the control group (OR = 0.20, 95% CI (0.12, 0.34), P＜0.000 01]. ConclusionCompared to the conventional therapy, viable BLE capsules/powder treatment improves the overall response rate and marked response rate in child patients with diarrhea secondary to recurrent respiratory infections, and reduces child patients′ diarrhea incidence.